Dept of Urologic Surgery Vanderbilt University Medical Center
Discuss the research studies that led to the approval of genomic testing for prostate cancer
Order appropriate genomic testing based on a patient's unique clinical situation
State the NCCN and AUA guidelines for genomic testing for prostate cancer
Discern the different prognostic clinical endpoints provided by various genomic tests
Recognize candidates for, and implications of, germline testing for prostate cancer
There are multiple genomic tests currently available for men to detect and risk stratify prostate cancer. The outcomes of these tests may lead to different detection strategies (observation, immediate biopsy, magnetic resonance imaging [MRI] etc.) and treatment decisions (active surveillance, surgery, radiation, adjuvant therapy etc). We will also discuss germline testing as inherited mutations have considerable implications for screening, treatment, genetic counseling and cascade testing of family members.
The availability and marketing of genomic testing has outpaced a reflective, evidence-based medicine approach to using these tests. Discussing the research studies that led to the approval of the various genomic tests, understanding the prognostic clinical endpoints they predict, reviewing current AUA and National Comprehensive Cancer Network® (NCCN®) guidelines for prostate cancer genomic testing, examining available validation studies and utilizing case-based scenarios will provide participants with the knowledge to assess these tests and apply them to their clinical practice.